Rossari Biotech Announces FY26 Results with Strategic Investments

Rossari Biotech announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a consolidated profit of ₹149.21 crore on revenue of ₹2,396.37 crore. The Board also recommended a final dividend of 25% (Re. 0.50 per share) for FY2025-26, pending shareholder approval.

The company's Board has approved establishing a new Research and Development (R&D) facility in Navi Mumbai to boost innovation and product development. Meanwhile, the planned capacity expansion project has been rescheduled for phased implementation over the next two years, suggesting a more flexible approach to growth and capital management.

Rossari Biotech is a significant player in India's specialty chemicals sector, operating across Home, Personal Care & Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN) segments. The investment in a new R&D center signals its commitment to future growth through enhanced innovation.

The company has a history of investing in capacity expansion. Previously, it announced significant enhancements at its subsidiaries Unitop Chemicals and Tristar Intermediates, targeting completion by Q4 FY25-26, with plans for 18,500 MTPA at Unitop and 3,600 MTPA at Tristar. Recent additions, such as 20,000 MTPA at its Dahej facility and 15,000 MTPA ethoxylation capacity at Unitop, were commissioned by October 2025.

In governance updates, Mr. Udeypaul Singh Gill has joined the Board as an Additional Director (Non-Executive, Independent). Regarding legal matters, Rossari Biotech received a final arbitration award in January 2026 concerning Unitop Chemicals, which directed the release of a tax refund with interest. The company assessed this award to have a limited financial impact.

Comparing with the previous fiscal year, consolidated revenue for FY25 stood at ₹2,095.2 crore, an increase of 14.4% to the FY26 revenue of ₹2,396.37 crore. Consolidated Profit After Tax for FY25 was ₹136.4 crore, a rise of 9.4% to ₹149.21 crore in FY26.

Investors will be watching the specific timelines for the phased capacity expansion and the operationalization of the new R&D facility. Performance updates from key segments like HPPC and TSC, particularly the anticipated recovery in textiles, will also be important. The company's ability to manage raw material price volatility and scale production efficiently amidst market demand will be crucial. Rossari competes in a landscape with peers such as Aarti Industries, Vinati Organics, Atul Ltd., and Galaxy Surfactants.